PL335378A1 - Derivatives of inverse hydroxamates as metaloprotease inhibitors - Google Patents

Derivatives of inverse hydroxamates as metaloprotease inhibitors

Info

Publication number
PL335378A1
PL335378A1 PL98335378A PL33537898A PL335378A1 PL 335378 A1 PL335378 A1 PL 335378A1 PL 98335378 A PL98335378 A PL 98335378A PL 33537898 A PL33537898 A PL 33537898A PL 335378 A1 PL335378 A1 PL 335378A1
Authority
PL
Poland
Prior art keywords
hydroxamates
inverse
derivatives
metaloprotease
inhibitors
Prior art date
Application number
PL98335378A
Other languages
English (en)
Inventor
Marc W Andersen
Robert Carl Andrews
Dulce Garrido Bubacz
Joseph Howing Chan
David John Cowan
Michael David Gaul
Darryl Lynn Mcdougald
David Lee Musso
Michael Howard Rabinowitz
Jennifer Badiang Stanford
Robert William Wiethe
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PL335378A1 publication Critical patent/PL335378A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Detergent Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL98335378A 1997-02-26 1998-02-24 Derivatives of inverse hydroxamates as metaloprotease inhibitors PL335378A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3911297P 1997-02-26 1997-02-26

Publications (1)

Publication Number Publication Date
PL335378A1 true PL335378A1 (en) 2000-04-25

Family

ID=21903750

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98335378A PL335378A1 (en) 1997-02-26 1998-02-24 Derivatives of inverse hydroxamates as metaloprotease inhibitors

Country Status (16)

Country Link
EP (1) EP1019386A1 (xx)
JP (1) JP2001513767A (xx)
KR (1) KR20000075681A (xx)
AP (1) AP9901631A0 (xx)
AR (1) AR013070A1 (xx)
AU (1) AU6822398A (xx)
BR (1) BR9807763A (xx)
CA (1) CA2281664A1 (xx)
HR (1) HRP980096A2 (xx)
IS (1) IS5159A (xx)
NO (1) NO994103L (xx)
PE (1) PE59199A1 (xx)
PL (1) PL335378A1 (xx)
TR (1) TR199902063T2 (xx)
WO (1) WO1998038179A1 (xx)
ZA (1) ZA981532B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
CN1298299A (zh) * 1998-02-07 2001-06-06 英国生物技术药物有限公司 抗菌剂
WO2000012466A1 (en) * 1998-08-26 2000-03-09 Glaxo Group Limited Formamide compounds as therapeutic agents
WO2000012083A1 (en) * 1998-08-26 2000-03-09 Glaxo Group Limited Formamides as therapeutic agents
GB9818621D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therapeutic agents
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
GB9918869D0 (en) * 1999-08-10 1999-10-13 British Biotech Pharm Antibacterial agents
JP2003081838A (ja) * 2001-09-11 2003-03-19 Rohto Pharmaceut Co Ltd グルコサミン製剤
EP2319518A1 (en) 2002-02-04 2011-05-11 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
US20060148839A1 (en) * 2003-02-11 2006-07-06 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and tace-inhibitors
WO2007092899A2 (en) * 2006-02-09 2007-08-16 The Burnham Institute Inhibitors of membrane type-1 matrix metalloproteinase for the treatment of insulin-dependent diabetes mellitus
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
WO2009118175A1 (en) 2008-03-25 2009-10-01 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CN102395562A (zh) 2009-04-14 2012-03-28 阿费克蒂斯制药股份公司 新的p2x7r拮抗剂及其用途
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
ES2656237T3 (es) 2011-04-19 2018-02-26 Alfama, Inc. Moléculas liberadoras de monóxido de carbono y usos de las mismas
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2013013179A1 (en) 2011-07-21 2013-01-24 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
WO2020070239A1 (en) 2018-10-04 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
CZ290145B6 (cs) * 1994-01-20 2002-06-12 British Biotech Pharmaceuticals Limited Inhibitory metaloproteinázy
GB9514867D0 (en) * 1995-07-20 1995-09-20 British Biotech Pharm Metalloproteinase inhibitors
ES2164264T3 (es) * 1995-11-23 2002-02-16 British Biotech Pharm Inhibidores de metaloproteinasas.

Also Published As

Publication number Publication date
KR20000075681A (ko) 2000-12-26
HRP980096A2 (en) 1998-12-31
AR013070A1 (es) 2000-12-13
EP1019386A1 (en) 2000-07-19
CA2281664A1 (en) 1998-09-03
BR9807763A (pt) 2000-02-22
NO994103D0 (no) 1999-08-25
TR199902063T2 (xx) 1999-12-21
WO1998038179A1 (en) 1998-09-03
PE59199A1 (es) 1999-06-24
AP9901631A0 (en) 1999-09-30
NO994103L (no) 1999-10-25
ZA981532B (en) 1999-08-24
AU6822398A (en) 1998-09-18
IS5159A (is) 1999-08-20
JP2001513767A (ja) 2001-09-04

Similar Documents

Publication Publication Date Title
PL335378A1 (en) Derivatives of inverse hydroxamates as metaloprotease inhibitors
PL333918A1 (en) Derivatives of 6-phenylpyryidil-2-amine useful as nos inhibitors
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
PL331856A1 (en) Heterocyclic inhibitors of metaloprotease
PL327569A1 (en) Promedications of thrombosin inhibitors
AU4429799A (en) Inhibitors of p38
AU1271297A (en) Inhibitor of ceramidase
ZA98376B (en) Sulfamide-metalloprotease inhibitors
HU9702036D0 (en) New heterocyclic compounds as inhibitors of leucocita-adhesion and wla-4-antagonists
EP1009415A4 (en) INHIBITORS OF $ g (b) -LACTAMASES AND THEIR USES
PL339551A1 (en) Derivatives of rezorcin
IL127260A0 (en) Hydroxy-phosphinyl derivatives useful as naaladase inhibitors
PL331047A1 (en) Novel amidinic derivatives and their application as inhibitors of thrombosin
PL342113A1 (en) Sulphonamidic derivatives useful as precursors of aspartil protease inhibitors
PL337697A1 (en) Farnesil-proteinous transferase inhibitors
PL331254A1 (en) Phosphonianic inhibitors of matrix metaloproteases
PL331795A1 (en) Heterocyclic metaloprotease inhibitors
PL337645A1 (en) Novel amidine derivatives and their application as thrombosin inhibitors
HU0900792D0 (en) Use of renin-angiotensin inhibitors
AU9317298A (en) Pyrrolidin-2-one compounds and their use as neuraminidase inhibitors
PL334975A1 (en) Application of gasto-intestinal lipase inhibitors
PL339176A1 (en) Derivatives of pyrrolopyrrolone as inhibitors of neutrophilic elastase
GB9425701D0 (en) Enzyme inhibitors
ZA983065B (en) Inhibitors of protein farnesyltranferase
HU9503783D0 (en) Squvalen syntetase inhibitors